Eris Lifesciences Limited Stock Price Today (NSE: ERIS)
Fundamental Score
Eris Lifesciences Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Eris Lifesciences Limited share price today is ₹1303.20, down 0.53% on NSE/BSE as of 16 September 2026. Eris Lifesciences Limited (ERIS) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹18.06K (Cr). The 52-week high for ERIS share price is ₹1740.00 and the 52-week low is ₹1200.00. At a P/E ratio of 27.72x, ERIS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.34% and a debt-to-equity ratio of 0.59.
Eris Lifesciences Limited Share Price Chart — NSE/BSE Historical Performance
Eris Lifesciences Limited share price chart: -4.93% return over the past month. 52-week high ₹1740.00, 52-week low ₹1200.00.
Eris Lifesciences Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1296.20 | ₹1324.70 | ₹1282.80 | ₹1303.20 | 15.10K (Cr) | |
| ₹1355.50 | ₹1359.90 | ₹1300.60 | ₹1310.10 | 44.18K (Cr) | |
| ₹1356.60 | ₹1362.00 | ₹1335.10 | ₹1355.50 | 24.97K (Cr) | |
| ₹1335.00 | ₹1360.90 | ₹1325.00 | ₹1356.60 | 39.51K (Cr) | |
| ₹1318.00 | ₹1339.00 | ₹1318.00 | ₹1335.00 | 42.16K (Cr) | |
| ₹1322.90 | ₹1333.80 | ₹1315.10 | ₹1324.70 | 28.74K (Cr) | |
| ₹1327.40 | ₹1341.00 | ₹1318.20 | ₹1324.30 | 27.45K (Cr) | |
| ₹1301.00 | ₹1332.20 | ₹1301.00 | ₹1321.70 | 69.11K (Cr) | |
| ₹1320.00 | ₹1336.70 | ₹1288.90 | ₹1303.50 | 74.40K (Cr) | |
| ₹1292.00 | ₹1349.90 | ₹1265.10 | ₹1288.90 | 1.53L (Cr) |
Eris Lifesciences Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1297.20 | ₹1362.00 | ₹1265.10 | ₹1303.20 | +0.46% | |
| ₹1353.00 | ₹1410.00 | ₹1292.00 | ₹1297.20 | -4.12% | |
| ₹1448.40 | ₹1499.00 | ₹1345.00 | ₹1354.70 | -6.47% | |
| ₹1400.00 | ₹1488.00 | ₹1337.60 | ₹1433.50 | +2.39% | |
| ₹1322.90 | ₹1530.00 | ₹1322.00 | ₹1399.00 | +5.75% | |
| ₹1312.90 | ₹1478.00 | ₹1200.00 | ₹1322.90 | +0.76% | |
| ₹1341.10 | ₹1375.90 | ₹1236.00 | ₹1297.20 | -3.27% | |
| ₹1375.00 | ₹1529.00 | ₹1316.20 | ₹1358.30 | -1.21% | |
| ₹1517.00 | ₹1563.00 | ₹1301.20 | ₹1375.50 | -9.33% | |
| ₹1586.00 | ₹1740.00 | ₹1469.10 | ₹1505.60 | -5.07% | |
| ₹1602.00 | ₹1700.00 | ₹1506.30 | ₹1595.40 | -0.41% | |
| ₹1585.00 | ₹1660.00 | ₹1520.00 | ₹1591.70 | +0.42% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Eris Lifesciences Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Eris Lifesciences Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ERIS across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.34%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.19%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (35.51%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 27.72 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (20.73%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (20.89% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Cash Generation (₹1215.54 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.85%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 26.74%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
2 factors identified
High Price-to-Book Ratio (6.22x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Liquidity Concerns (Current Ratio: 0.89)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
Eris Lifesciences Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Eris Lifesciences Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Eris Lifesciences LimitedEris Lifescienc...Selected✓ ERIS • 540596 | 45.4/100 | ₹1303.20₹1303 | ₹18062.35₹18062.35 | 27.72Average 27.7 Average | 18.34%Good 18.34% Good | 15.19%Good 15.19% Good | 0.59Good 0.6 Good | 11.77%Good 11.77% Good | 20.89%Excellent 20.89% Excellent | 0.50% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Eris Lifesciences Limited PE Ratio History
Historical price-to-earnings ratio for ERIS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹25.81 | ₹1505.60 | 58.3x |
| FY 2024 | ₹28.79 | ₹1373.70 | 47.7x |
| FY 2023 | ₹28.07 | ₹910.00 | 32.4x |
| FY 2022 | ₹29.88 | ₹647.25 | 21.7x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Eris Lifesciences Limited Dividend History
Annual cash dividends paid by ERIS — dividend yield 0.50%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹100.05 Cr |
| FY 2023 | ₹99.91 Cr |
| FY 2022 | ₹81.62 Cr |
| FY 2021 | ₹74.68 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Eris Lifesciences Limited Quarterly Performance
Latest quarterly metrics for ERIS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
12.97%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
20.73%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
20.89%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
11.77%
Compounded annual net profit growth over 5 years
Eris Lifesciences Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ERIS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Eris Lifesciences Limited Financial Statements
Annual income statement, balance sheet and cash flow for Eris Lifesciences Limited (ERIS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Eris Lifesciences Limited
About ERIS (Eris Lifesciences Limited)
Eris Lifesciences Limited (ERIS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a ...current market capitalisation of ₹18.06K (Cr). Eris Lifesciences Limited has delivered a Return on Equity (ROE) of 18.34% and a ROCE of 15.19%. The debt-to-equity ratio stands at 0.59, reflecting the company's capital structure. Investors tracking ERIS share price can monitor key metrics including P/E ratio, promoter holding of 54.85%, and quarterly earnings growth.
Company Details
Key Leadership
ERIS Share Price: Frequently Asked Questions
What is the current share price of Eris Lifesciences Limited?
Eris Lifesciences Limited (ERIS) trades at ₹1303.20 on NSE and BSE. Market cap ₹18.06K (Cr). Educational data only.
What is the P/E ratio of Eris Lifesciences Limited?
Eris Lifesciences Limited has a P/E of 27.72x vs industry average 34.89x.
What is the Bull Run score for Eris Lifesciences Limited?
Eris Lifesciences Limited has a Bull Run score of 45.4/100 based on 25+ financial parameters.
Does Eris Lifesciences Limited pay dividends?
Eris Lifesciences Limited has a dividend yield of 0.50%. Past dividends don't guarantee future payments.
What is the ROE of Eris Lifesciences Limited?
Eris Lifesciences Limited has ROE of 18.34%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Eris Lifesciences Limited?
Eris Lifesciences Limited has debt-to-equity of 0.59.
Is Eris Lifesciences Limited a good investment?
Bull Run gives Eris Lifesciences Limited a score of 45.4/100. This is not investment advice — consult a SEBI-registered advisor.